JP2015505535A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015505535A5 JP2015505535A5 JP2014553448A JP2014553448A JP2015505535A5 JP 2015505535 A5 JP2015505535 A5 JP 2015505535A5 JP 2014553448 A JP2014553448 A JP 2014553448A JP 2014553448 A JP2014553448 A JP 2014553448A JP 2015505535 A5 JP2015505535 A5 JP 2015505535A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- e4orf1
- adenovirus
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261588959P | 2012-01-20 | 2012-01-20 | |
| US61/588,959 | 2012-01-20 | ||
| PCT/US2013/022126 WO2013109876A1 (en) | 2012-01-20 | 2013-01-18 | Enhanced glycemic control using ad36e4orf1 and akt1 inhibitor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015505535A JP2015505535A (ja) | 2015-02-23 |
| JP2015505535A5 true JP2015505535A5 (enExample) | 2016-02-25 |
| JP6175076B2 JP6175076B2 (ja) | 2017-08-02 |
Family
ID=47664431
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014553448A Expired - Fee Related JP6175076B2 (ja) | 2012-01-20 | 2013-01-18 | Ａｄ３６ｅ４ｏｒｆ１およびａｋｔ１阻害剤を使用した血糖コントロールの向上 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9433659B2 (enExample) |
| EP (1) | EP2804616B1 (enExample) |
| JP (1) | JP6175076B2 (enExample) |
| AU (1) | AU2013209580B2 (enExample) |
| BR (1) | BR112014017683A2 (enExample) |
| CA (1) | CA2865202A1 (enExample) |
| WO (1) | WO2013109876A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025080777A1 (en) * | 2023-10-10 | 2025-04-17 | Texas Tech University System | Ad36e4orf1 peptide fragments as anti-diabetic agents |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1954131B1 (en) * | 2005-11-30 | 2014-04-02 | Board of Supervisors of Louisiana State University and Agricultural and Mechanical College | Adenovirus 36 e4 orf 1 gene and protein and their uses |
| AR064010A1 (es) | 2006-12-06 | 2009-03-04 | Merck & Co Inc | Inhibidores de la actividad de la akt |
-
2013
- 2013-01-18 AU AU2013209580A patent/AU2013209580B2/en not_active Ceased
- 2013-01-18 CA CA2865202A patent/CA2865202A1/en not_active Abandoned
- 2013-01-18 JP JP2014553448A patent/JP6175076B2/ja not_active Expired - Fee Related
- 2013-01-18 US US14/370,317 patent/US9433659B2/en active Active
- 2013-01-18 BR BR112014017683A patent/BR112014017683A2/pt not_active IP Right Cessation
- 2013-01-18 WO PCT/US2013/022126 patent/WO2013109876A1/en not_active Ceased
- 2013-01-18 EP EP13702690.2A patent/EP2804616B1/en not_active Not-in-force
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Vázquez-Domínguez et al. | Molecular therapies for inherited retinal diseases—current standing, opportunities and challenges | |
| Haller et al. | Mx GTPases: dynamin-like antiviral machines of innate immunity | |
| Theis et al. | Lentiviral delivery of miR-133b improves functional recovery after spinal cord injury in mice | |
| EP3049116B1 (en) | Nanoparticle-mediated gene delivery, genomic editing and ligand-targeted modification in various cell populations | |
| Amet et al. | Human growth hormone–transferrin fusion protein for oral delivery in hypophysectomized rats | |
| Song et al. | Evidence for an RNA chaperone function of polypyrimidine tract-binding protein in picornavirus translation | |
| Van Gestel et al. | shRNA-induced saturation of the microRNA pathway in the rat brain | |
| JP2014504150A5 (enExample) | ||
| JP2016500648A5 (enExample) | ||
| JP2017538401A5 (enExample) | ||
| JP2016500513A5 (enExample) | ||
| JP2015513897A5 (enExample) | ||
| JP2015530404A5 (enExample) | ||
| JP2014511698A5 (enExample) | ||
| MX359953B (es) | Ácido nucleico que comprende o que codifica un tallo-rizo de histona y una secuencia poli (a) o una señal de poliadenilación para incrementar la expresión de una proteína terapéutica codificada. | |
| JP2018528237A5 (enExample) | ||
| WO2011036442A3 (en) | Thrombin c- terminal polypeptides and uses thereof for treating inflammation coagulation disorders | |
| RU2019100525A (ru) | Векторная система на основе аденоассоциированного вируса | |
| IN2012DN02981A (enExample) | ||
| JP2014526881A5 (enExample) | ||
| JP2015522264A5 (enExample) | ||
| Jeon et al. | HIF1A overexpression using cell-penetrating DNA-binding protein induces angiogenesis in vitro and in vivo | |
| Kim et al. | NO‐induced downregulation of HSP10 and HSP60 expression in the postischemic brain | |
| WO2006085583A1 (ja) | 細胞透過性ペプチド | |
| JP2013531681A5 (enExample) |